The Foundation for Orthopaedics and Regenerative Medicine
CompanyUnited States
The Foundation for Orthopaedics and Regenerative Medicine develops one asset, in phase 1 (AlloRx in frailty). Mostly cell therapy acting on inflammation and stem cell maintenance; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 7
- Trials
- 0
- Signals
Pipeline
1Cultured allogeneic adult umbilical cord derived mesenchymal stem cells infused intravenously to improve frailty.
Phase 1, Cell therapy, Inflammation, Stem cell maintenance, frailty
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials7
- Similar companies6